Affordable Access

Access to the full text

Circulating tumor DNA is detectable in canine histiocytic sarcoma, oral malignant melanoma, and multicentric lymphoma

Authors
  • Prouteau, Anaïs1
  • Denis, Jérôme Alexandre2, 3
  • De Fornel, Pauline4
  • Cadieu, Edouard1
  • Derrien, Thomas1
  • Kergal, Camille1
  • Botherel, Nadine1
  • Ulvé, Ronan1
  • Rault, Mélanie1
  • Bouzidi, Amira2
  • François, Romain4
  • Dorso, Laetitia5
  • Lespagnol, Alexandra6
  • Devauchelle, Patrick4
  • Abadie, Jérôme5
  • André, Catherine1
  • Hédan, Benoît1
  • 1 IGDR (Institut de génétique et développement de Rennes) UMR6290, Rennes, 35000, France , Rennes (France)
  • 2 Sorbonne University, Paris, France , Paris (France)
  • 3 APHP Pitié-Salpêtrière Hospital, Paris, France , Paris (France)
  • 4 Micen Vet, Créteil, France , Créteil (France)
  • 5 Laboniris, Nantes, France , Nantes (France)
  • 6 Hospital of Rennes, Rennes, France , Rennes (France)
Type
Published Article
Journal
Scientific Reports
Publisher
Springer Nature
Publication Date
Jan 13, 2021
Volume
11
Issue
1
Identifiers
DOI: 10.1038/s41598-020-80332-y
Source
Springer Nature
License
Green

Abstract

Circulating tumor DNA (ctDNA) has become an attractive biomarker in human oncology, and its use may be informative in canine cancer. Thus, we used droplet digital PCR or PCR for antigen receptor rearrangement, to explore tumor-specific point mutations, copy number alterations, and chromosomal rearrangements in the plasma of cancer-affected dogs. We detected ctDNA in 21/23 (91.3%) of histiocytic sarcoma (HS), 2/8 (25%) of oral melanoma, and 12/13 (92.3%) of lymphoma cases. The utility of ctDNA in diagnosing HS was explored in 133 dogs, including 49 with HS, and the screening of recurrent PTPN11 mutations in plasma had a specificity of 98.8% and a sensitivity between 42.8 and 77% according to the clinical presentation of HS. Sensitivity was greater in visceral forms and especially related to pulmonary location. Follow-up of four dogs by targeting lymphoma-specific antigen receptor rearrangement in plasma showed that minimal residual disease detection was concordant with clinical evaluation and treatment response. Thus, our study shows that ctDNA is detectable in the plasma of cancer-affected dogs and is a promising biomarker for diagnosis and clinical follow-up. ctDNA detection appears to be useful in comparative oncology research due to growing interest in the study of natural canine tumors and exploration of new therapies.

Report this publication

Statistics

Seen <100 times